Abstract #3864
Prediction of MGMT promotor methylation status in glioblastoma by contrast-enhanced T1-weighted intensity image
Takahiro Sanada1, Manabu Kinoshita1,2, Takahiro Sasaki3,4, Shota Yamamoto1,5, Seiya Fujikawa6, Shusei Fukuyama1, Nobuhide Hayashi4, Junya Fukai3, Yoshiko Okita7,8, Masahiro Nonaka8,9, Takehiro Uda10, Hideyuki Arita2,7, Kanji Mori11, Kenichi Ishibashi12, Koji Takano2,13, Namiko Nishida14, Tomoko Shofuda15, Ema Yoshioka15, Daisuke Kanematsu15, Mishie Tanino16, Yoshinori Kodama17, Masayuki Mano18, and Yonehiro Kanemura8,15
1Neurosurgery, Asahikawa Medical University, Asahikawa, Japan, 2Neurosurgery, Osaka International Cancer Institute, Osaka, Japan, 3Neurological Surgery, Wakayama Medical University School of Medicine, Wakawayma, Japan, 4Neurosurgery, Wakayama Rosai Hospital, Wakayama, Japan, 5Neurosurgery, Osaka General Medical Center, Osaka, Japan, 6Neurosurgery, Japanese Red Cross Kitami Hospital, Kitami, Japan, 7Neurosurgery, Osaka University Graduate School of Medicine, Osaka, Japan, 8Neurosurgery, National Hospital Organization Osaka National Hospital, Osaka, Japan, 9Neurosurgery, Kansai Medical University, Hirakata, Japan, 10Neurosurgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan, 11Neurosurgery, Yao Municipal Hospital, Yao, Japan, 12Neurosurgery, Osaka City General Hospital, Osaka, Japan, 13Neurosurgery, Toyonaka Municipal Hospital, Toyonaka, Japan, 14Neurosurgery, Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan, 15Biomedical Research and Innovation, Institute for Clinical Research, National Hospital Organization Osaka National Hospital, Osaka, Japan, 16Diagnostic Pathology, Asahikawa Medical University Hospital, Asahikawa, Japan, 17Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka, Japan, 18Central Laboratory and Surgical Pathology, National Hospital Organization Osaka National Hospital, Osaka, Japan
Synopsis
Keywords: Tumors (Pre-Treatment), Tumor, Glioma, Glioblastoma
Motivation: Non-invasive prediction of GBM’s pMGMT methylation status is still challenging despite recent advancements of image analysis.
Goal(s): This study explored a clinically feasible imaging biomarker that represents GBM’s pMGMT methylation status with external validation.
Approach: Two qualitative imaging features, namely the “Thickened structure” and the “Methylated contrast phenotype,” were identified as valuable to this means.
Results: GBMs presenting both imaging features exhibited a significantly high odds ratio, favoring pMGMT methylation in the exploratory and validation cohorts with a sensitivity and specificity of approximately 0.3-0.4 and 0.8. The easy clinical application of the proposed imaging features is expected to facilitate better preoperative GBM characterization.
Impact: GBMs presenting both imaging features, namely the “Thickened structure” and the “Methylated contrast phenotype,” exhibited a significantly high odds ratio, favoring pMGMT methylation in the exploratory and validation cohorts with a sensitivity and specificity of approximately 0.3-0.4 and 0.8.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.
